Stem cell lens therapeutics - Guangdong ProCapZoom Biosciences
Latest Information Update: 30 May 2025
At a glance
- Originator Guangdong ProCapZoom Biosciences
- Class Immunotherapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Graft-versus-host disease
Most Recent Events
- 30 Apr 2025 Preclinical trials in Graft-versus-host disease in China (Intraocular)
- 20 Apr 2025 Guangdong ProCapZoom Biosciences plans a phase 0 trial for Graft versus host disease in China in April 2025 (Intraocular) (NCT06952114)
- 01 Sep 2023 Guangdong Procapzoom Biosciences has patent filled for Stem cell lens Worldwide